NPX-267 by NextPoint Therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Related Posts

AbbVie achieves win for migraine prevention drug Aquipt...

Aug 18, 2023

Junshi Biosciences, Dr. Reddy’s partner to develop and ...

May 8, 2023

Obesity-related cardiovascular deaths tripled in the la...

Sep 8, 2023